What are the latest FDA‑approved updates to the management of small‑cell lung cancer (SCLC) in adults, including limited‑stage and extensive‑stage disease and options for relapsed or refractory disease?

Latest Updates to Small Cell Lung Cancer Treatment

The most significant recent update is FDA approval of tarlatamab, a novel bispecific T-cell engager, for relapsed/refractory extensive-stage SCLC after at least two prior lines including platinum-based chemotherapy, demonstrating a 40% response rate with a remarkable 9.7-month median duration of response. 1

Limited-Stage SCLC: Consolidation Immunotherapy

Patients with limited-stage SCLC who complete concurrent chemoradiotherapy without disease progression should receive consolidation durvalumab for up to 2 years (strong recommendation, moderate evidence quality). 1 This represents a paradigm shift in limited-stage disease management, with recent trials demonstrating nearly 2 years improvement in median overall survival. 2

Key Implementation Points:

• Durvalumab is indicated only if there are no contraindications to immunotherapy 1
• Even patients with ECOG performance status 3-4 due to SCLC may be offered consolidation durvalumab if their performance status improves after chemoradiotherapy (conditional recommendation, low evidence quality) 1

Extensive-Stage SCLC: First-Line Treatment

Carboplatin/etoposide combined with immunotherapy (atezolizumab or durvalumab) is the current standard first-line treatment, with modest but meaningful improvements in overall survival. 3, 2

Atezolizumab Dosing Update:

• The FDA approved different dosing options for atezolizumab maintenance 1
• 1,200 mg maintenance atezolizumab remains the Category 1 recommendation (based on clinical trial data) 1
• 1,680 mg maintenance dosing is also acceptable but carries a lower evidence category 1

Relapsed/Refractory SCLC: Major Treatment Advances

Tarlatamab - The Game Changer

For patients with relapsed SCLC after at least two prior systemic regimens (including platinum-based therapy), tarlatamab is now a preferred single-agent option alongside topotecan and lurbinectedin. 1

Tarlatamab Efficacy:

• Overall response rate: 40% (95% CI 31%-51%) 1, 4
• Median duration of response: 9.7 months (substantially longer than other agents) 1
• Response rate in platinum-resistant disease: 52% 1
• Response rate in platinum-sensitive disease: 31% 1
• 9-month progression-free survival rate: 28% 1
• 9-month overall survival rate: 68% 1

Tarlatamab Dosing Protocol:

• Initial dose: 1 mg IV on day 1 of cycle 1 1
• Step-up dosing: 10 mg IV on days 8 and 15 of cycle 1 1
• Maintenance: 10 mg IV every 2 weeks thereafter until progression or unacceptable toxicity 1

Critical Safety Considerations - Boxed Warning:

Tarlatamab carries serious risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), requiring mandatory 24-hour inpatient monitoring after the first two doses of cycle 1 (days 1 and 8). 1, 4

• CRS occurred in 51% of patients (mostly grade 1-2; only 1% grade 3) 1
• CRS symptoms: fever (97%), hypotension (20%), hypoxia (17%) 1
• CRS median onset: 13 hours; median duration: 4 days 1
• Nearly all CRS events occurred during cycle 1 1
• ICANS occurred in 8% (all grade 1-2), median onset 5 days 1
• Grade ≥3 treatment-related adverse events: 26% 1

Treatment Algorithm for Relapsed SCLC

For Chemotherapy-Free Interval <90 Days (Platinum-Resistant):

Preferred single-agent options: topotecan, lurbinectedin, or tarlatamab (strong recommendation, moderate evidence quality). 1 Single-agent therapy is preferred over multiagent regimens due to better risk-benefit balance. 1

For Chemotherapy-Free Interval ≥90 Days (Platinum-Sensitive):

Rechallenge with platinum-based regimen is preferred, but single-agent systemic therapy (topotecan, lurbinectedin, or tarlatamab) is also appropriate. 1

Additional Second-Line Options

The NCCN guidelines provide extensive options for relapsed disease regardless of timing, though these carry Category 2A recommendations: 1

Other recommended regimens include:

• Paclitaxel 1
• Docetaxel 1
• Irinotecan 1
• Temozolomide (especially for brain metastases with methylated MGMT) 1
• CAV (cyclophosphamide/doxorubicin/vincristine) 1
• Oral etoposide 1
• Vinorelbine 1
• Gemcitabine 1
• Bendamustine (Category 2B) 1

Checkpoint Inhibitors in Relapsed Disease - Important Nuance

Nivolumab and pembrolizumab are Category 2A recommendations for relapsed SCLC, but with critical caveats: 1

• The FDA removed subsequent therapy indications for nivolumab/pembrolizumab because phase III trials failed to show overall survival improvement 1
• However, NCCN still recommends them in select settings: patients with limited-stage SCLC who progress and have NOT previously received checkpoint inhibitors may benefit 1
• Avoid checkpoint inhibitors in patients who relapse after 6 months while on maintenance atezolizumab or durvalumab 1
• The panel considers them as effective as and sometimes better than other options, with less toxicity 1

Supportive Care Innovation

Trilaciclib, a short-acting CDK 4/6 inhibitor, is FDA-approved for administration prior to platinum/etoposide or topotecan-containing regimens to reduce chemotherapy-induced myelosuppression. 5, 3 This represents a novel supportive care strategy to maintain treatment intensity and quality of life.

Common Pitfalls and Clinical Pearls

Sequencing Dilemma:

There are currently no head-to-head trials comparing tarlatamab, lurbinectedin, and topotecan, making optimal sequencing unclear. 1 The ongoing DeLLphi-304 trial comparing tarlatamab with standard chemotherapy will provide guidance. 1 Cross-trial comparisons suggest both lurbinectedin and tarlatamab are more effective than topotecan, but tarlatamab's 9.7-month duration of response is substantially longer than other agents. 1

Patient Selection for Tarlatamab:

• Requires ECOG PS 0-1 1
• Patients with asymptomatic, previously treated, stable brain metastases are eligible 1
• Exclude patients with: interstitial lung disease, active pneumonitis, history of severe infusion reactions, severe immune-related adverse events, or grade ≥2 pneumonitis from previous immunotherapy 1

Immunotherapy Maintenance Considerations:

Do not use checkpoint inhibitors for relapsed disease if the patient progressed while on maintenance atezolizumab or durvalumab - this represents acquired resistance to the immunotherapy mechanism. 1